Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 7/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313813 | 0.84 | VCAM1 (0.56) | VCAM1TDP1TSHRMAPK1ALDH1A1 | |
| SCHEMBL30583791 | 0.82 | TDP1 (0.60) | VCAM1TDP1TSHRMAPK1ALDH1A1 | |
| SCHEMBL894816 | 0.82 | TDP1 (0.60) | VCAM1TDP1TSHRMAPK1ALDH1A1 | |
| SCHEMBL8390568 | 0.79 | VCAM1 (0.51) | VCAM1TDP1TSHRMAPK1MERTK | |
| SCHEMBL7860943 | 0.79 | VCAM1 (0.51) | VCAM1TDP1TSHRMAPK1ALDH1A1 | |
| SCHEMBL9899689 | 0.79 | TDP1 (0.42) | VCAM1TDP1TSHRMAPK1MEN1 | |
| SCHEMBL272708 | 0.79 | TDP1 (0.60) | VCAM1TDP1TSHRMAPK1ALDH1A1 | |
| Hydroxyamine SCHEMBL6264479 | 0.78 | TDP1 (0.55) | VCAM1TDP1TSHRMAPK1ALDH1A1 | |
| SCHEMBL6581238 | 0.76 | VCAM1 (0.51) | VCAM1TDP1TSHRMAPK1MERTK | |
| SCHEMBL28571587 | 0.76 | VCAM1 (0.51) | VCAM1TDP1TSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007087068-A2 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1753730-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-08 | — | — | US | disclosed |
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| WO-2004099190-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| EP-1222187-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458712-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| US-6770639-B2 | CELL PROLIFERATIVE; AUTOIMMUNE DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2003051277-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| US-6506769-B2 | Pyridine -imidazole, -thiazole or -oxazole derivatives; treating autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1222187-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001025238-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP3, DPP4, DPP7 | VCAM1 4654/4885TDP1 2133/4885TSHR 2727/4885 |
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | PARK7, HYPK, BCL2A1 | VCAM1 1969/4885TDP1 495/4885TSHR 3322/4885 |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | VCAM1 356/4885TDP1 1816/4885TSHR 1362/4885 |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | VCAM1 4654/4885TDP1 2133/4885TSHR 2727/4885 |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | VCAM1 356/4885TDP1 1816/4885TSHR 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.